Breakthrough medicines by rational design

A vast number of drug targets with the potential to favorably alter disease course, remain out of therapeutic reach. We started with a pledge to tackle the most challenging drug targets in modern medicine. Our efforts have given rise to a portfolio of first-in-class immune-oncology and antiviral medicinal assets that are poised to alter the treatment paradigm for several life-threatening diseases.

Investment to date in
portfolio entities

$ 0 M
Innovative discovery
programs
0

“Undruggable” targets successfully “drugged”

0

Investment to date in
portfolio entities

$ 0 M
Innovative discovery
programs
0

“Undruggable” targets successfully “drugged”

0

At Our Core We Are a Discovery Engine

We are pursuing some of the most sought-after targets in drug discovery

Our goal is to bring drug candidates with novel mechanisms of action to a stage closer to clinical translation, making them more suitable for strategic co-development. We are developing small molecule drugs that demonstrate target engagement and deliver a profound disease-modifying effect.

IMMUNO-ONCOLOGY

Our Approach

Our discovery platform can tailor novel and clinically relevant compounds for some of the most exciting targets that remain out of therapeutic reach. We focus on clinically validated targets, leveraging cutting-edge biophysical and orthogonal technologies, solving high-resolution atomic resolution structures of drugs in complex with their protein targets to accelerate the discovery process.

Rigorous Target
Selection

READ MORE

We focus on novel diseases targets with validated clinical relevance that fit our discovery platform. This offers an unmatched potential in revolutionizing the standard of care.

Leveraging Orthogonal
Technologies

READ MORE

By merging cell and structure-based data with information-driven strategies, we have built a cutting-edge drug discovery engine.

Structure Based
Drug Design

READ MORE

We harness advanced structural biology, biochemical, and biophysical technologies to design first-in-class therapeutics against clinically relevant drug targets.

Locations

Pledge has an international footprint with presence in two of the most innovative ecosystems in the US and EU. We are headquartered in the Greater Boston area in the US and also have research labs in Flanders, Belgium.